Symbols / IPHA
IPHA Chart
About
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 159.33M |
| Enterprise Value | 125.51M | Income | -46.05M | Sales | 12.64M |
| Book/sh | 0.07 | Cash/sh | 0.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 174 | IPO | — |
| P/E | — | Forward P/E | -3.04 | PEG | — |
| P/S | 12.61 | P/B | 25.74 | P/C | — |
| EV/EBITDA | -2.52 | EV/Sales | 9.93 | Quick Ratio | 2.08 |
| Current Ratio | 2.21 | Debt/Eq | 525.45 | LT Debt/Eq | — |
| EPS (ttm) | -0.65 | EPS next Y | -0.56 | EPS Growth | — |
| Revenue Growth | -60.60% | Earnings | 2026-03-26 | ROA | -25.92% |
| ROE | -271.37% | ROIC | — | Gross Margin | -243.65% |
| Oper. Margin | -5.23% | Profit Margin | 0.00% | Shs Outstand | 93.72M |
| Shs Float | 60.34M | Short Float | 0.25% | Short Ratio | 10.17 |
| Short Interest | — | 52W High | 2.63 | 52W Low | 1.57 |
| Beta | 0.57 | Avg Volume | 23.06K | Volume | 777.00 |
| Target Price | $5.75 | Recom | None | Prev Close | $1.72 |
| Price | $1.70 | Change | -1.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.75
Mean price target
2. Current target
$1.70
Latest analyst target
3. DCF / Fair value
$-3.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.70
Low
$2.00
High
$8.00
Mean
$5.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-29 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-10-29 | reit | BTIG | Buy → Buy | $8 |
| 2025-09-18 | down | Leerink Partners | Outperform → Market Perform | $2 |
| 2025-09-18 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-04-24 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-09 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-06-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-04-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-06-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-03-24 | reit | HC Wainwright & Co. | — → Buy | $12 |
- Cancer immunotherapy firm Innate Pharma set for Miami investor spotlight - Stock Titan Wed, 18 Feb 2026 06
- IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers - Stocktwits Mon, 10 Nov 2025 08
- Innate Pharma (Nasdaq: IPHA) joins Leerink Partners Global Healthcare Conference 2026 - Stock Titan Wed, 18 Feb 2026 11
- Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire hu, 13 Nov 2025 08
- Pharma Boom: Innate Pharma Stock’s Rapid Ascent - StocksToTrade Mon, 10 Nov 2025 08
- Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops - Nasdaq Wed, 17 Sep 2025 07
- Trading Action: Whats the fair value of IPHA stock - 2025 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn Mon, 16 Feb 2026 14
- Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch - Stocktwits Mon, 10 Nov 2025 08
- and Announces Sanofi’s Intention to Make a Strategic Investment in the Company - Business Wire Wed, 23 Apr 2025 07
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 - Yahoo Finance Sun, 21 Dec 2025 08
- Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com Mon, 10 Nov 2025 08
- Innate Pharma Completes Major Regulatory Filings: Access Full 2024 Financial Reports Now - Stock Titan Wed, 30 Apr 2025 07
- AMT May 15th Options Begin Trading - Nasdaq Fri, 13 Feb 2026 15
- Major FDA Breakthrough: Innate's Novel Lymphoma Drug Lacutamab Accelerates Toward Approval - Stock Titan Mon, 17 Feb 2025 08
- Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire Mon, 10 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -47.14M | -4.40M | 29.53M | -42.90M |
| TotalUnusualItems | 232.00K | 2.56M | -41.80M | 2.33M |
| TotalUnusualItemsExcludingGoodwill | 232.00K | 2.56M | -41.80M | 2.33M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -49.47M | -7.57M | -57.97M | -45.48M |
| ReconciledDepreciation | 1.99M | 5.09M | 45.41M | 4.60M |
| EBITDA | -46.91M | -1.84M | -12.28M | -40.57M |
| EBIT | -48.91M | -6.93M | -57.68M | -45.17M |
| NetInterestIncome | 1.87M | 2.54M | 258.00K | 15.00K |
| InterestExpense | 566.00K | 640.00K | 288.00K | 312.00K |
| InterestIncome | 2.44M | 3.18M | 546.00K | 327.00K |
| NormalizedIncome | -49.70M | -10.13M | -16.17M | -47.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -49.47M | -7.57M | -58.10M | -52.81M |
| TotalExpenses | 64.20M | 64.57M | 66.00M | 59.94M |
| TotalOperatingIncomeAsReported | -51.58M | -12.67M | -57.42M | -47.83M |
| DilutedAverageShares | 81.05M | 84.11M | 79.64M | 79.54M |
| BasicAverageShares | 81.05M | 84.11M | 79.64M | 79.54M |
| DilutedEPS | -0.61 | -0.09 | -0.73 | -0.66 |
| BasicEPS | -0.61 | -0.09 | -0.73 | -0.66 |
| DilutedNIAvailtoComStockholders | -49.47M | -7.57M | -58.10M | -52.81M |
| NetIncomeCommonStockholders | -49.47M | -7.57M | -58.10M | -52.81M |
| NetIncome | -49.47M | -7.57M | -58.10M | -52.81M |
| NetIncomeIncludingNoncontrollingInterests | -49.47M | -7.57M | -58.10M | -52.81M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | -131.00K | -7.33M |
| NetIncomeContinuousOperations | -49.47M | -7.57M | -57.97M | -45.48M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -49.47M | -7.57M | -57.97M | -45.48M |
| OtherIncomeExpense | 232.00K | 2.56M | -41.80M | 2.33M |
| SpecialIncomeCharges | 0.00 | 0.00 | -41.00M | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 41.00M | 0.00 |
| GainOnSaleOfSecurity | 232.00K | 2.56M | -805.00K | 2.33M |
| NetNonOperatingInterestIncomeExpense | 1.87M | 2.54M | 258.00K | 15.00K |
| InterestExpenseNonOperating | 566.00K | 640.00K | 288.00K | 312.00K |
| InterestIncomeNonOperating | 2.44M | 3.18M | 546.00K | 327.00K |
| OperatingIncome | -51.58M | -12.67M | -16.43M | -47.83M |
| OperatingExpense | 64.20M | 64.57M | 66.00M | 59.94M |
| OtherOperatingExpenses | 284.00K | -3.20M | -131.00K | -3.06M |
| ResearchAndDevelopment | 51.98M | 56.02M | 51.66M | 47.00M |
| SellingGeneralAndAdministration | 11.93M | 11.75M | 14.47M | 15.99M |
| GeneralAndAdministrativeExpense | 11.93M | 11.75M | 14.47M | 15.99M |
| OtherGandA | 3.38M | 2.91M | 4.24M | 5.11M |
| SalariesAndWages | 8.56M | 8.84M | 10.23M | 10.88M |
| TotalRevenue | 12.62M | 51.90M | 49.58M | 12.11M |
| OperatingRevenue | 12.56M | 51.89M | 50.20M | 12.11M |
| Line Item | 2024-12-31 | 2023-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 18.57K | 18.57K | 18.57K | |
| OrdinarySharesNumber | 83.81M | 80.84M | 79.54M | 79.54M |
| ShareIssued | 83.83M | 80.86M | 79.54M | 79.56M |
| TotalDebt | 31.00M | 39.89M | 42.25M | 44.25M |
| TangibleBookValue | 8.83M | 51.48M | 52.60M | 63.25M |
| InvestedCapital | 39.45M | 90.96M | 94.36M | 148.88M |
| WorkingCapital | 52.76M | 108.38M | 98.49M | 58.37M |
| NetTangibleAssets | 8.83M | 51.48M | 52.60M | 63.25M |
| CapitalLeaseObligations | 375.00K | 835.00K | 2.04M | 2.82M |
| CommonStockEquity | 8.83M | 51.90M | 54.15M | 107.44M |
| TotalCapitalization | 31.02M | 82.51M | 93.08M | 118.93M |
| TotalEquityGrossMinorityInterest | 8.83M | 51.90M | 54.15M | 107.44M |
| StockholdersEquity | 8.83M | 51.90M | 54.15M | 107.44M |
| OtherEquityInterest | -1.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 27.00K | 495.00K | 819.00K | 456.00K |
| OtherEquityAdjustments | 27.00K | 495.00K | 819.00K | 456.00K |
| RetainedEarnings | -386.36M | -336.89M | -330.32M | -272.21M |
| AdditionalPaidInCapital | 390.98M | 384.25M | 379.64M | 375.22M |
| CapitalStock | 4.19M | 4.04M | 4.01M | 3.98M |
| CommonStock | 4.19M | 4.04M | 4.01M | 3.98M |
| TotalLiabilitiesNetMinorityInterest | 102.22M | 123.29M | 145.14M | 160.06M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 69.24M | 83.65M | 103.81M | 80.17M |
| OtherNonCurrentLiabilities | 41.13M | 45.03M | 52.99M | 33.00M |
| EmployeeBenefits | 2.73M | 2.44M | 2.55M | 2.98M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 2.73M | 2.44M | 2.55M | 2.98M |
| NonCurrentDeferredLiabilities | 2.83M | 4.62M | 7.92M | 30.44M |
| NonCurrentDeferredRevenue | 2.83M | 4.62M | 7.92M | 25.41M |
| NonCurrentDeferredTaxesLiabilities | 9.01M | 8.57M | 5.03M | |
| LongTermDebtAndCapitalLeaseObligation | 22.29M | 30.96M | 40.15M | 13.50M |
| LongTermCapitalLeaseObligation | 104.00K | 350.00K | 1.22M | 2.01M |
| LongTermDebt | 22.18M | 30.61M | 38.93M | 11.49M |
| LongTermProvisions | 274.00K | 603.00K | 198.00K | 253.00K |
| CurrentLiabilities | 32.98M | 39.64M | 41.34M | 79.89M |
| OtherCurrentLiabilities | 7.44M | 7.65M | 10.22M | 7.42M |
| CurrentDeferredLiabilities | 616.00K | 5.87M | 6.56M | 12.50M |
| CurrentDeferredRevenue | 616.00K | 5.87M | 6.56M | 12.50M |
| CurrentDebtAndCapitalLeaseObligation | 8.71M | 8.94M | 2.10M | 30.75M |
| CurrentCapitalLeaseObligation | 271.00K | 485.00K | 824.00K | 804.00K |
| CurrentDebt | 8.44M | 8.45M | 1.28M | 29.94M |
| OtherCurrentBorrowings | 8.44M | 8.45M | 1.28M | 29.94M |
| CurrentProvisions | 207.00K | 171.00K | 1.54M | 647.00K |
| PayablesAndAccruedExpenses | 16.01M | 17.02M | 20.91M | 28.57M |
| Payables | 16.01M | 17.02M | 20.91M | 28.57M |
| OtherPayable | 1.12M | 1.44M | 1.28M | 6.38M |
| TotalTaxPayable | 6.96M | 7.02M | 5.98M | 7.46M |
| AccountsPayable | 7.92M | 8.56M | 13.66M | 14.73M |
| TotalAssets | 111.06M | 175.19M | 199.29M | 267.50M |
| TotalNonCurrentAssets | 25.32M | 27.18M | 59.47M | 129.24M |
| OtherNonCurrentAssets | 575.00K | 87.00K | 152.00K | 150.00K |
| NonCurrentDeferredAssets | 9.01M | 8.57M | 5.03M | |
| NonCurrentDeferredTaxesAssets | 9.01M | 8.57M | 5.03M | |
| NonCurrentAccountsReceivable | 9.33M | 10.55M | 14.10M | 29.82M |
| InvestmentsAndAdvances | 10.28M | 9.80M | 35.12M | 39.88M |
| InvestmentinFinancialAssets | 10.28M | 9.80M | 35.12M | 39.88M |
| FinancialAssetsDesignatedasFairValueThroughProfitorLossTotal | 9.80M | 35.12M | 39.88M | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 416.00K | 1.55M | 44.19M |
| OtherIntangibleAssets | 416.00K | 1.55M | 44.19M | |
| NetPPE | 5.13M | 6.32M | 8.54M | 10.17M |
| GrossPPE | 5.13M | 6.32M | 8.54M | 10.17M |
| Leases | 1.27M | 1.68M | ||
| ConstructionInProgress | 0.00 | 0.00 | 0.00 | 6.00K |
| OtherProperties | 2.86M | 3.38M | 4.30M | 5.19M |
| LandAndImprovements | 1.02M | 1.28M | 4.24M | |
| Properties | 0.00 | 0.00 | 0.00 | 4.98M |
| CurrentAssets | 85.74M | 148.01M | 139.83M | 138.26M |
| OtherCurrentAssets | 1.00K | 2.00K | 1.00K | |
| PrepaidAssets | 3.33M | 9.07M | 7.32M | 4.95M |
| Receivables | 1.64M | 46.49M | 31.02M | 13.47M |
| OtherReceivables | 89.00K | 104.00K | 61.00K | 814.00K |
| TaxesReceivable | 904.00K | 31.15M | 27.88M | 11.81M |
| AccountsReceivable | 650.00K | 15.23M | 3.08M | 846.00K |
| CashCashEquivalentsAndShortTermInvestments | 80.77M | 92.46M | 101.48M | 119.84M |
| OtherShortTermInvestments | 14.37M | 21.85M | 17.26M | 16.08M |
| CashAndCashEquivalents | 66.40M | 70.61M | 84.22M | 103.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.29M | -34.91M | -20.28M | -59.79M |
| RepaymentOfDebt | -8.94M | -2.36M | -2.03M | -2.07M |
| IssuanceOfDebt | 0.00 | 0.00 | 28.70M | |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -391.00K | -2.35M | -1.12M | -1.33M |
| EndCashPosition | 66.40M | 70.61M | 84.22M | 103.76M |
| BeginningCashPosition | 70.61M | 84.22M | 103.76M | 136.79M |
| EffectOfExchangeRateChanges | -505.00K | 274.00K | -428.00K | -483.00K |
| ChangesInCash | -3.70M | -13.89M | -19.10M | -32.55M |
| FinancingCashFlow | -6.01M | -1.97M | -1.83M | 26.82M |
| CashFlowFromContinuingFinancingActivities | -6.01M | -1.97M | -1.83M | 26.82M |
| NetOtherFinancingCharges | 1.00K | |||
| InterestPaidCFF | 0.00 | 0.00 | -312.00K | |
| ProceedsFromStockOptionExercised | 2.93M | 395.00K | 198.00K | 499.00K |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | -8.94M | -2.36M | -2.03M | 26.63M |
| NetLongTermDebtIssuance | -8.94M | -2.36M | -2.03M | 26.63M |
| LongTermDebtPayments | -8.94M | -2.36M | -2.03M | -2.07M |
| LongTermDebtIssuance | 0.00 | 0.00 | 28.70M | |
| InvestingCashFlow | 9.20M | 20.63M | 1.88M | -917.00K |
| CashFlowFromContinuingInvestingActivities | 9.20M | 20.63M | 1.88M | -917.00K |
| NetOtherInvestingChanges | 1.00K | 63.00K | -1.00K | 39.00K |
| InterestReceivedCFI | 0.00 | 0.00 | 367.00K | |
| NetInvestmentPurchaseAndSale | 9.59M | 22.77M | 3.00M | 0.00 |
| SaleOfInvestment | 9.59M | 22.77M | 3.00M | 0.00 |
| PurchaseOfInvestment | 0.00 | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -2.00M | -587.00K | -401.00K |
| PurchaseOfIntangibles | 0.00 | -2.00M | -587.00K | -401.00K |
| NetPPEPurchaseAndSale | -391.00K | -201.00K | -535.00K | -922.00K |
| SaleOfPPE | 0.00 | 150.00K | 0.00 | 7.00K |
| PurchaseOfPPE | -391.00K | -351.00K | -535.00K | -929.00K |
| OperatingCashFlow | -6.90M | -32.56M | -19.16M | -58.46M |
| CashFlowFromContinuingOperatingActivities | -6.90M | -32.56M | -19.16M | -58.46M |
| ChangeInWorkingCapital | 39.16M | -32.09M | -12.50M | -9.88M |
| ChangeInOtherWorkingCapital | -23.43M | -6.06M | ||
| ChangeInOtherCurrentLiabilities | 22.80M | -6.27M | ||
| ChangeInPayablesAndAccruedExpense | -7.66M | -946.00K | ||
| ChangeInPayable | -7.66M | -946.00K | ||
| ChangeInAccountPayable | -7.66M | -946.00K | ||
| ChangeInReceivables | -4.20M | 3.39M | ||
| ChangesInAccountReceivables | -4.20M | 3.39M | ||
| OtherNonCashItems | -356.00K | 6.00K | 133.00K | -927.00K |
| StockBasedCompensation | 3.94M | 4.26M | 4.25M | 2.62M |
| UnrealizedGainLossOnInvestmentSecurities | -1.33M | -1.59M | 1.37M | -987.00K |
| ProvisionandWriteOffofAssets | -293.00K | -966.00K | 839.00K | 4.00K |
| DepreciationAmortizationDepletion | 1.99M | 5.09M | 45.41M | 4.60M |
| DepreciationAndAmortization | 1.99M | 5.09M | 45.41M | 4.60M |
| OperatingGainsLosses | -541.00K | 308.00K | -547.00K | -1.07M |
| PensionAndEmployeeBenefitExpense | 324.00K | 285.00K | 365.00K | 437.00K |
| GainLossOnInvestmentSecurities | -912.00K | -1.14M | ||
| NetForeignCurrencyExchangeGainLoss | -885.00K | 544.00K | -912.00K | -1.14M |
| GainLossOnSaleOfPPE | 20.00K | 470.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -49.47M | -7.57M | -58.10M | -52.81M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IPHA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|